Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: Affinity, efficacy and potential implications for treatment of schizophrenia

International Journal of Neuropsychopharmacology

Volumn 8, Issue 3, 2005, Pages 341-356

  Newman Tancredi, Adrian ^a   Assié, Marie Bernadette ^a   Leduc, Nathalie ^a   Ormière, Anne Marie ^a   Danty, Nathalie ^a   Cosi, Cristina ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

5 HT1A receptors; 35S GTP S; Aripiprazole; Atypical antipsychotics; Clozapine; G proteins; Hippocampus

Indexed keywords

1 [2 (4 FLUOROBENZAMIDO)ETHYL] 4 (7 METHOXY 1 NAPHTHYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; 5 CARBAMOYLTRYPTAMINE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ADENYLATE CYCLASE; ARIPIPRAZOLE; BAY 3732; BIFEPRUNOX; BUSPIRONE; CLOZAPINE; DIHYDROERGOTAMINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; FLESINOXAN; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; REPINOTAN; RISPERIDONE; ROXINDOLE; SARIZOTAN; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; THIORIDAZINE; TIOSPIRONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR BINDING; SCHIZOPHRENIA;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADENYLATE CYCLASE; ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HELA CELLS; HUMANS; PHOSPHORUS ISOTOPES; PROTEIN BINDING; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECOMBINANT PROTEINS; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION; TRITIUM;

EID: 22344431960     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704005000     Document Type: Article

References (76)

1. 35S]GTPγS binding in rat hippocampal membranes. European Journal of Pharmacology 343, 303-312.
2. 1A receptor agonist properties of the antipsychotic nemonapride: comparison with bromerguride and clozapine. European Journal of Pharmacology 334, 141-147.
3. 1A receptors and intrinsic activity. European Journal of Pharmacology 386, 97-103.
4. Assié M-B, Ravailhe V, Faucillon V, Newman-Tancredi A (2004). Effects of antipsychotics with diverse dopamine D2 and serotonin 5-HT1A properties on cerebral dopamine and serotonin levels in rats. 24th Collegium Internationale NeuroPsychopharmacologicum (CINP) Congress, Paris, Poster P02.506.
5. 3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. European Journal of Pharmacology 237, 183-189.
6. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? Journal of Psychopharmacology 15, 37-46.
7. 1A receptor by clozapine measured using PET scanning. Journal of Psychopharmacology 14 (Suppl.), PG20.
8. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083-1152.
9. 1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. Journal of Neural Transmission 111, 113-126.
10. 1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 46, 1121-1129.
11. Bradbury MJ, Giracello DR, Chapman DF, Holtz G, Schaffhauser H, Rao SP, Varney MA, Anderson JJ (2003). Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: interaction with serotonergic systems. Neuropharmacology 44, 562-572.
12. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochemistry International 30, 565-574.
13. 1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology 166, 234-240.
14. 1A receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 28, 2064-2076.
15. 1A receptors. European Journal of Pharmacology 401, 9-15.
16. 1A receptors expressed in HeLa cells. European Journal of Pharmacology 433, 55-62.
17. 1A receptors. Psychopharmacology 162, 168-177.
18. 1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Research 989, 42-51.
19. 1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28, 1889-902.
20. 1A receptors in human post-mortem brain. European Journal of Pharmacology 386, 313-315.
21. 1A receptor. Journal of Biological Chemistry 264, 14848-14852.
22. 1A receptors. Drugs Fut 27 (Suppl. A). XVIIth International Symposium on Medicinal Chemistry.
23. 1A receptor agonist: in vitro and in vivo neuropharmacology. European Neuropsychopharmacology 12 (Suppl. 3), P.2.053.
24. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET (1991). An open trial of buspirone added to neuroleptics in schizophrenic patients. Journal of Clinical Psychoparmacology 11, 193-197.
25. 1A antagonist, WAY100,635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology 127, 245-254.
26. 1A antagonist, WAY 100635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology 14, 547-552.
27. 1A receptors in prefrontal cortex and temporal cortices of brains from patients with chronic schizophrenia. Life Sciences 48, 355-363.
28. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SCR, Sharma T (1999). Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proceedings of the National Academy of Sciences USA 96, 13432-13437.
29. 1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Research 858, 252-263.
30. Inoue T, Domae M, Yamada K, Furukawa T (1996). Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4- dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. Journal of Pharmacology Experimental Therapeutics 277, 137-143.
31. 1A agonist, blocks haloperidol-induced catalepsy by an action of raphe nuclei medianus and dorsalis. Neuropharmacology 27, 515-518.
32. Jain AK, Kelwala S, Moore N, Gershon S (1987). A controlled clinical trial of tiaspirone in schizophrenia. International Clinical Psychopharmacology 2, 129-133.
33. 1A receptors. European of Neuropsychopharmacology 12, S293.
34. 1A receptor. European Journal of Pharmacology 441, 137-140.
35. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA (2004). In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. European Journal of Pharmacology 483, 45-53.
36. 2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. European Journal of Pharmacology 313, 25-34.
37. 1A properties: evidence for lowered EPS liability. 24th Collegium Internationale NeuroPsychopharmacologicum (CINP) Congress, Paris, Poster 02.503.
38. 1A receptor activation and antidepressant-like effects: F13714 has high efficacy and marked antidepressant potential. European Journal of Pharmacology 420, 103-112.
39. Kroeze WK, Roth BL (1998). The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biological Psychiatry 44, 1128-1142.
40. 2 receptor antagonism with serotonin reuptake inhibition. Washington, DC: Society for Neuroscience. Program No. 894.2.
41. Leysen J (2000). Receptor profile of antipsychotics. In: Ellenbroek BA, Cools AR (Eds.), Atypical Antipsychotics (pp. 57-81). Basel, Switzerland: Birkhäuser Verlag.
42. Li Z, Ichikawa J, Dai J, Meltzer HY (2004). Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. European Journal of Pharmacology 493, 75-83.
43. Long SK, Feenstra R, Kruse CG, Van Vliet BJ (2000). DU 127090: a highly potent, atypical dopamine receptor ligand - partial agonist character in neurochemistry assays in vivo. European Neuropsychopharmacology 10 (Suppl. 3), P.2.037.
44. 1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology 172, 415-421.
45. 1A receptors in human brain tissue. European Journal of Pharmacology 221, 397-398.
46. 1A receptor agonist BAY x 3702 in vitro and in vivo. Brain Research 888, 150-157.
47. McCreary AC, Glennon J, Tuinstra T, Herremans AHJ, Van der Heyden JAM, Feenstra R, Long SK, Kruse CG (2002). SLV313: a novel antipsychotic with additional antidepressant and anxiolytic-like actions. European Neuropsychopharmacology 12 (Suppl. 3), P.2.046.
48. McMillen BA, Scott SM, Davanzo E (1988). Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. Journal of Pharmacology 40, 885-887.
49. Meneses A (1999). 5-HT system and cognition. Neuroscience Biobehavioral Review 23, 1111-1125.
50. 1A receptors. Journal of Pharmacology Experimental Therapeutics 295, 853-861.
51. 1A agonist properties. I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. Journal of Pharmacology Experimental Therapeutics 286, 1341-1355.
52. 1A agonist properties: II Functional profile in comparison to clozapine and haloperidol. Journal of Pharmacology Experimental Therapeutics 286, 1356-1373.
53. Moore NC, Meyendorff E, Yeragani V, LeWitt PA, Gershon S (1987). Tiaspirone in schizophrenia. Journal of Clinical Psychopharmacology 7, 98-101.
54. Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burns KD, Molinoff PB, Tottori K, Altar CA, Kikuchi T (2003). Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European Journal of Pharmacology 472, 89-97.
55. i3 activation: conformational selection by high-efficacy agonists and relationship to trafficking of receptor signalling. Molecular Pharmacology 62, 590-601.
56. 35S]GTPγS binding study. European Journal of Pharmacology 355, 245-256.
57. 1A receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Archives Pharmacology 368, 188-199.
58. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. European Journal of Pharmacology 453, 217-221.
59. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144, 20-29.
60. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biological Psychiatry 48, 229-237.
61. 1A receptor activation. European Journal of Pharmacology 338, R3-5.
62. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews Drug Discovery 3, 353-359.
63. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schultz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA, Heym J (1995). Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Journal of Pharmacology Experimental Therapeutics 275, 101-113.
64. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu L-X, Sibley DR, Roth BL, Mailman R (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411.
65. 1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatric Annals 26, 88-93.
66. Sovner R, Parnell-Sovner N (1989). Use of buspirone in the treatment of schizophrenia. Journal of Clinical Psychopharmacology 9, 61-62.
67. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY (2001a). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. American Journal of Psychiatry 158, 1722-1725.
68. 1A agonist, on memory function in schizophrenia. Biological Psychiatry 49, 861-868.
69. 1A receptors are increased in post-mortem prefrontal cortex in schizophrenia. Brain Research 708, 209-214.
70. 11C]WAY-100635. Archives General Psychiatry 59, 514-520.
71. 2 receptor antagonism with serotonin reuptake inhibition. Washington, DC: Society for Neuroscience. Program No. 894.19.
72. Van Vliet BJ, Mos J, Van der Heijden, Feenstra R, Kruse CG, Long SK (2000a). DU 127090: a highly potent, atypical dopamine receptor ligand - a putative potent full spectrum antipsychotic with low EPS potential. European Neuropsychopharmacology 10 (Suppl. 3), P.2.034.
73. 2 receptors in vitro. European Neuropsychopharmacology 10 (Suppl. 3), P.2.035.
74. Wadenberg MLG, Young KA, Richter JT, Hicks PB (1999). Effects of local applications of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology 38, 151-156.
75. 1A serotonin receptors in the rat brain. Brain Research 756, 84-91.
76. 1A receptor binding in amygdala of schizophrenia. Biological Psychiatry 55, 439-444.